Sudan virus (genus Ebolavirus) is lethal, yet no monoclonal antibody is known to neutralize it. We here describe antibody 16F6 that neutralizes Sudan virus and present its structure bound to the trimeric viral glycoprotein. Unexpectedly, the 16F6 epitope overlaps that of KZ52, the only other antibody against the GP 1,2 core to be visualized to date. Furthermore, both antibodies against this crucial epitope bridging GP1-GP2 neutralize at a post-internalization step-probably fusion.
and the resulting GP1-GP2 pair trimerizes to form a ~450-kDa envelope spike on the viral surface. GP1 is responsible for attaching the virus to new host cells, whereas GP2 mediates fusion of the virus envelope with cellular endosomal membranes. GP1 contains base, head, glycan-cap and mucin-like domains. The head subdomain contains putative receptor-binding regions and is capped by the heavily glycosylated glycan-cap and mucin-like domains. In the endosome, a flexible loop containing GP1 residues 190-213 is cleaved by host cathepsins 10, 11 . This cleavage releases the glycan-cap and mucin-like domains from GP1. Also in the endosome, GP2 releases from GP1 and undergoes irreversible conformational changes that drive fusion with host endosomal membranes. GP2 contains an N-terminal peptide, a hairpin-forming fusion loop and two heptad repeats connected by a functionally important linker. The first heptad repeat of GP2 is wound around the base of GP1 in a metastable, prefusion-specific conformation (Supplementary Fig. 1 ).
To generate antibodies specific for SUDV, we vaccinated BALB/c laboratory mice with Venezuelan equine encephalitis virus (VEEV) replicons bearing SUDV (strain Boniface) GP 1,2 and boosted them with γ-radiation-inactivated SUDV-Boniface. We found that among the resulting monoclonal antibodies, IgG 1 16F6 was directed against a conformational epitope on GP 1,2 , was specific for SUDV and reacted with at least two different SUDV variants, Boniface and Gulu. We crystallized a trimeric complex of SUDV-Gulu GP 1,2 in complex with a 16F6 Fab fragment in order to map the epitope of 16F6 and understand its SUDV specificity.
We expressed SUDV-Gulu GP 1,2 for crystallization by transiently transfecting human embryonic kidney 293T cells. No mutations of the N-linked glycosylation sites were necessary, in contrast to previous studies that required these mutations for crystallization of EBOV GP 1,2 (refs. 12,13) . SUDV-Gulu GP 1,2 -16F6 crystallized in the space group I23 with one monomeric GP 1,2 -Fab complex in the asymmetric unit (Supplementary Methods and Supplementary Table 1 ). The biologically relevant trimer was formed by crystallographic symmetry, and GP 1,2 was in its supposed metastable, prefusion conformation (Fig. 1) .
In general, the SUDV GP 1,2 crystals are more well-ordered than those of EBOV GP 1,2 , allowing visualization of outer portions of the glycan cap and the linker region between the N-and C-terminal heptad repeats of GP2, neither of which were previously observed (Fig. 1c) 13 . The linker region contains a CX 6 CC motif, in which the first two cysteines-Cys601 and Cys608-form an intra-GP2 disulfide bond that anchors the intervening polypeptide in a cloverleaf loop (Fig. 1d) . The third cysteine (Cys609) anchors the GP2 cloverleaf to b r i e F c o m m u n i c at i o n s Cys53 in the base of GP1 (Fig. 1d) . The shape and location of these disulfide-anchored loops suggest that they restrict the flexibility between N-terminal and C-terminal heptad repeats to an elbow-like range of motion, perhaps coupling the rotation of GP1 with the movement of the second heptad repeat of GP2 during membrane fusion.
The N-terminal half of the GP2 fusion loop is only 33% conserved between the two viruses and adopts a different, lower-hanging conformation (Fig. 1c) . By contrast, the C-terminal half of the fusion loop is conserved in sequence and structure between SUDV and EBOV, and it is anchored to the outside of the trimer by Arg89 of the neighboring monomer's GP1-head subdomain (Supplementary Fig. 2 ). In SUDV, Arg89 forms five hydrogen bonds and a hydrophobic contact to the fusion loop. These contacts are conserved between SUDV and EBOV structures, and Arg89 is probably critical for clamping the fusion loop in place to anchor the trimer in its prefusion conformation ( Supplementary Fig. 2a ).
In the proposed three-dimensional receptor-binding site of GP1 (head subdomain), regions that project are conserved in sequence, whereas regions that are recessed differ in sequence between SUDV and EBOV ( Fig. 2a and Supplementary Figs. 3 and 4) . The conserved, projecting regions (residues 114-120, 144-147, 149 and 172-173) may thus delineate surfaces expected to bind to the shared receptor.
More of the cathepsin-cleavage-site polypeptide is visible in the SUDV structure than in the EBOV structure. The position of the newly observed residues (190-192 and 212-213) immediately above and below the fusion loop suggests that the GP2 fusion loop could be tethered by the 190-213 polypeptide (Supplementary Fig. 2b ). Regions of GP 1,2 that surround the cathepsin cleavage site and that a Putative receptorbinding sites
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SUDV GP2 HR1-HR2 linker and GP1-GP2 CX 6 CC motif monomers. SUDV GP1-GP2 is shown in green for GP1 and white for GP2, and EBOV GP1-GP2 is shown in blue for GP1 and yellow for GP2. The SUDV structure includes additional regions of the glycan cap (top), the linker between heptad repeats 1 and 2 (HR1 and HR2) and the CX 6 CC motif (bottom), although the N terminus of GP2 is disordered. (d) The linker region between HR1 and HR2 forms two disulfide bonds per monomer, one linking GP1 to GP2 (Cys53-Cys609) and one within GP2 (Cys601-Cys608).
All figures were generated with PyMOL and VMD. 
Unexpectedly, these sequence variations cause distinctly different electrostatic charges in the GP 1,2 peplomers. SUDV GP 1,2 is acidic overall, especially at the base of the trimer where the metastable GP 1,2 assembly intertwines. By contrast, EBOV GP 1,2 is more neutral and is slightly basic where GP1 and GP2 intertwine (Fig. 2b,c and Supplementary Fig. 3 ).
The crystal structure reveals that mAb 16F6 binds to the base of the SUDV GP 1,2 trimer and directly connects the base of GP1 to the stem of the internal fusion loop of GP2 ( Fig. 1 and Supplementary  Fig. 2c) . Unexpectedly, the epitope of 16F6 overlaps that of mAb KZ52, thus far the only other antibody against the core of any ebolavirus GP 1,2 to be structurally mapped 13 (Fig. 3) . KZ52 is specific for EBOV GP 1,2 and was previously identified in a library derived from a human survivor of the 1995 outbreak in Kikwit, Zaire 3 . The 16F6 and KZ52 epitopes have the central nine residues in common: 42-44 of GP1 and 513, 550-553 and 556 of GP2 (Fig. 3b) . Six of these nine residues are conserved between SUDV and EBOV ( Supplementary  Fig. 4) . Fundamentally, although the two antibodies were produced against distinct viruses and in different immunological contexts (one by a vaccinated mouse and the other by a naturally infected human), these antibodies both recognized overlapping epitopes and arrived at a shared structural solution for neutralizing ebolaviruses.
In our study, 16F6 recognized native GP 1,2 on the surface of cells infected with Sudan virus (Supplementary Fig. 5a,e) . Plaque reduction neutralization tests (PRNT) illustrated that 16F6 confers a > 99% reduction of SUDV plaques (100 plaque-forming units (PFUs)) at 20 µg ml −1 (Supplementary Fig. 5b,e) . Plaque reduction occurred in the presence or absence of the complement, indicating that binding of 16F6 alone was sufficient to block SUDV infection in vitro. Furthermore, intraperitoneal treatment of SCID mice with 100 µg of 16F6 every 5 d after SUDV infection delayed the death of mice by ~4 d (P < 0.0001; see Supplementary Fig. 5c,e) .
We pseudotyped SUDV or EBOV GP 1,2 onto vesicular stomatitis Indiana virus (VSIV) to allow a direct comparison of the ability of 16F6 and KZ52 to neutralize otherwise identical virions carrying the cognate surface antigen for each antibody. The neutralization activity of 16F6 was somewhat better than that of KZ52: >99% versus ~90% reduction in 293T cell transduction at equal concentrations ( Supplementary  Fig. 5d ). Improvements in neutralization capacity are critical for providing immunotherapeutics against ebolaviruses, doses of a single PFU of which can be lethal to primates.
We conducted separate attachment and internalization assays, and these indicated that GP 1,2 -pseudotyped VSIV attach to and enter Vero E6 cells even in the presence of saturating quantities of 16F6 or KZ52 (Supplementary Fig. 6a) , and that KZ52 neutralizes VP30-deleted, biologically contained EBOV 14 at a post-entry step (see Supplementary Fig. 6b ; a biologically contained Sudan virus is not yet available). Consequently, antibodies against the shared 16F6 and KZ52 site must neutralize at a post-attachment, post-internalization step. Another step in the ebolavirus life cycle is cleavage of GP1 by cathepsins in the endosome 15, 16 . However, in our study, neither 16F6 nor KZ52 inhibited cathepsin L cleavage of either recombinant or viral surface GP1. Even in the presence of a ten-fold molar excess of KZ52 and 16F6, SUDV and EBOV GP 1,2 were fully digested by cathepsin L within 30 min and 60 min, respectively (Supplementary Fig. 7) .
Because 16F6 and KZ52 were found to function after internalization and did not inhibit cathepsin L cleavage, we think two possible mechanisms of inhibition remain: 16F6 and KZ52 may inhibit the function of some other unidentified factor, such as a co-receptor, or 16F6 and KZ52 may prevent the conformational changes in GP 1,2 required for membrane fusion. Our structural evidence supports the latter: both 16F6 and KZ52 physically link GP1 to GP2 and are specific for their prefusion conformation. Furthermore, the conformational changes in GP2 required for membrane fusion cannot occur while 16F6 or KZ52 remain bound. Indeed, the greater neutralization capacity of 16F6 may be related to its more effective linkage of GP1 to GP2. The GP 1,2 surface buried by 16F6 binding is composed of 60% GP1 and 40% GP2. By contrast, the GP 1,2 surface buried by KZ52 is composed of 20% GP1 and 80% GP2. We think it is important to note that these antibodies are likely to remain bound to GP 1,2 in the endosome: crystals of the EBOV GP 1,2 -KZ52 complex generated at pH 4.8 show unit-cell dimensions and space group identical to those of complexes developed at neutral or basic pH 12 , and GP 1,2 pretreated at pH 5.0 is well recognized by KZ52 (ref. 13) . Hence, pH alone is insufficient to separate GP1 from GP2.
This more well-ordered GP 1,2 structure allowed us to predict conformational rearrangements that may occur during membrane fusion of all ebolaviruses. Arg89 is proximal to the proposed receptor-binding site in the GP1 head. Its hold on the neighboring monomer's fusion loop must be released for fusion to occur, an action that could be accomplished directly by receptor binding or indirectly by conformational change that is transmitted through neighboring residues that bind receptor, or it could occur by continued enzymatic processing of GP1. Subsequent unwinding of the fusion loops from the outside of the trimer could be facilitated by cathepsin cleavage of the 190-213 loop, which may loosely tether GP2 in place ( Supplementary  Fig. 2b) . Motion of the fusion loops may be coupled to unwinding of the C-terminally linked heptad repeat 1 (HR1) from its GP1 spool 17, 18 and to the subsequent rotation of HR2 toward the target cell to form a six-helix bundle (Supplementary Fig. 1) .
Antibodies against the fusion subunits of influenza A virus hemagglutinin (HA) are known to block viral fusion 19, 20 . Notably, the anti-HA antibodies recognize only the fusion subunit, whereas 16F6 and KZ52 bind both the fusion subunit and the receptor-binding subunits of the glycoprotein and physically anchor them together. Hence, the shared epitope of 16F6 and KZ52 suggests a unique structural strategy by which antibodies inhibit viral infection.
In summary, we have demonstrated efficacy in vitro and in vivo of the first antibody shown to neutralize Sudan virus, and we have crystallized it in complex with the oligomeric, prefusion SUDV (Gulu) GP 1,2 . This structure and accompanying mechanistic analysis reveal new insights into ebolavirus entry and demonstrate that antibodies elicited in two unique host species by different scenarios bind overlapping epitopes and function at a similar post-entry step. These overlapping epitopes may indicate a crucial site for neutralization of ebolaviruses. Our work further suggests that for viruses in general, successful immunotherapy and vaccine design may depend on targeting antibodies that anchor glycoprotein subunits together and prevent the conformational changes required for fusion. 
